During South Africa’s COVID-19 hard lockdown, rising star scientist Dr Sandile Cele spent his Christmas holidays in a laboratory. Soon the 35-year-old became the first to successfully grow the beta variant of SARS-CoV-2 in the lab. Biénne Huisman spoke to Cele about how he did this, the string of accolades he received since, and his leap from a modest upbringing to the global scientific stage.
According to the World Health Organization, of the roughly 10 million people who fall ill with TB annually, over 80% survive, in most cases due to a six-month treatment course. Unfortunately, as with long COVID, being cured is not always the last hurdle and many people go on to struggle with post-TB lung disease. Tiyese Jeranji asked local experts about this sometimes-neglected area of TB care.
An experimental COVID-19 vaccine currently in Phase I trials being run by the University of Cape Town has a unique design that might allow it to offer better protection against current and future variants of the SARS-CoV-2 virus. Elri Voigt provides an update on the trial and unpacks the science behind this vaccine candidate.
The head of the South African arm of a key COVID-19 vaccine clinical trial is “full of pride” for the teams’ part in the research which has shown the vaccine candidate to be more than 90% effective according to early findings released this week. It however remains unclear whether the vaccine will be available in South Africa once registered. Adele Baleta reports.